Dr. Nathan Rose is responsible for Oxitec's programs to develop and implement novel vector control solutions for malaria vectors in Africa and Central America.  Previously, with responsibility for Oxitec’s global regulatory efforts, he led the team that in 2020 received the EPA’s approval for the first field release of genetically modified mosquitoes in the state of Florida. He has also spearheaded the successful effort to de-regulate both our leading mosquito product and our self-limiting Fall Armyworm in Brazil.

Nathan joined Oxitec as an R&D group leader in 2016 and, before that, had a career as an academic researcher at the University of Oxford, where he worked on the design of drugs targeting epigenetic enzymes involved in human cancers, where his research led to over 30 peer-reviewed publications. He received his MSc in Chemistry from Rhodes University in South Africa, and a DPhil in Chemical Biology from the University of Oxford.